Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Now in effect: Preferred products for long-acting colony-stimulating factors

November 18, 2022

​Effective November 1, 2022, the following long-acting colony-stimulating factors are designated as preferred products for members enrolled in Independence Administrators commercial programs and Independence Blue Cross commercial and Medicare Advantage programs:

  • Fulphila® (pegfilgrastim-jmdb)  
  • Neulasta® (pegfilgrastim)           
  • Ziextenzo® (pegfilgrastim-bmez)             

All other long-acting colony-stimulating factors are considered nonpreferred, including:

  • Fylnetra® (pegfilgrastim-pbbk)
  • Nyvepria® (pegfilgrastim-apgf)
  • Rolvedon™ (eflapegrastim-xnst)
  • Stimufend® (pegfilgrastim-fpgk)
  • Udenyca® (pegfilgrastim-cbqv)

The following medical policies are being updated to address these preferred and nonpreferred designations:

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.